The 'normobaric oxygen paradox': A simple way to induce endogenous erythropoietin production and concomitantly raise hemoglobin levels in anemic patients

Transfusion Alternatives in Transfusion Medicine

Volumn 11, Issue 1, 2010, Pages 39-42

  Balestra, Costantino ^a   Germonpré, Peter ^a,b   Lafere, Pierre ^a,b   Ciccarella, Yannick ^c   van der linden, Philippe ^c  

^a Haute Ecole Bruxelles Brabant   (Belgium)

^b QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; HEMOGLOBIN; PACLITAXEL;

ANEMIA; BREAST CANCER; CYTOKINE PRODUCTION; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; NEUROPROTECTION; OXYGEN BREATHING; OXYGEN CONCENTRATION; OXYGEN TENSION; OXYGEN THERAPY; PRIORITY JOURNAL;

EID: 77952485464     PISSN: 12959022     EISSN: 1778428X     Source Type: Journal    
DOI: 10.1111/j.1778-428X.2010.01127.x     Document Type: Letter

References (13)

1. Bursi F, Barbieri A, Politi L. Perioperative red blood cell transfusion and outcome in stable patients after elective major vascular surgery. Eur J Vasc Endovasc Surg 2009, 37:311-18.
2. Ruhl H, Bein G, Sachs UJ. Transfusion-associated graft-versus-host disease. Transfus Med Rev 2009, 23:62-71.
3. Merchionne F, Dammacco F. Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives. Br J Haematol 2009, 146:127-41.
4. Balestra C, Germonpre P, Poortmans JR, Marroni A. Serum erythropoietin levels in healthy humans after a short period of normobaric and hyperbaric oxygen breathing: the 'normobaric oxygen paradox'. J Appl Physiol 2006, 100:512-18.
5. Haddad JJ. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002, 14:879-97.
6. Haddad JJ, Land SC. O(2)-evoked regulation of HIF-1alpha and NF-kappaB in perinatal lung epithelium requires glutathione biosynthesis. Am J Physiol Lung Cell Mol Physiol 2000, 278:L492-503.
7. McPherson RJ, Juul SE. Recent trends in erythropoietin-mediated neuroprotection. Int J Dev Neurosci 2008, 26:103-11.
8. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 2008, 29:258-67.
9. Hare GM, Tsui AK, McLaren AT. Anemia and cerebral outcomes: many questions, fewer answers. Anesth Analg 2008, 107:1356-70.
10. Burk R. Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO). Med Hypotheses 2007, 69:1200-4.
11. Bokemeyer C, Aapro MS, Courdi A. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007, 43:258-70.
12. Corwin HL, Gettinger A, Pearl RG. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002, 288:2827-35.
13. Port RE, Ding RW, Fies T, Scharer K. Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia. Br J Clin Pharmacol 1998, 46:461-6.